New Delhi, Aug 31 (PTI) Biotechnology major Biocon on Monday said one of its subsidiaries and Mylan NV have launched insulin glargine injection, with brand name Semglee, in the US market.

Biocon Biologics India and Mylan NV have launched the product in vial and pre-filled pen presentations in the US, Biocon said in a statement.

Also Read | West Bengal Govt Extends Lockdown in Containment Zones Till Sep 30, Metro Services to be Resumed in Graded Manner From Sep 8.

Semglee, which has received final approval from the US Food and Drug Administration (FDA), has an identical amino acid sequence to Sanofi's Lantus, a drug used to control high blood sugar, it added.

"The commercialisation of our insulin glargine in the US represents another milestone achievement for Biocon in making insulin-based therapy increasingly accessible for people with diabetes globally," Biocon Executive Chairperson Kiran Mazumdar-Shaw said.

Also Read | Sensex Crashes 839 Points As India-China Border Tensions Flare Up.

The company is confident that along with its long-standing partner Mylan, it will be able to address the needs of millions of patients living with diabetes in the US, she added.

Biocon has been expanding affordable access to biosimilar insulins to patients in Japan, Australia, Europe, India and key emerging markets, Shaw said.

"The US launch of Semglee takes us closer to realising our aspiration of reaching 'one in five' insulin dependent people with diabetes worldwide," she added.

Biocon Biologics CEO Christiane Hamacher said the company's focus on developing and manufacturing global quality insulins enables it to address the growing needs of diabetes patients.

"We believe the US market represents a great opportunity for us and expect Semglee to contribute significantly to our goal of impacting 5 million patients' lives and achieving USD 1 billion revenue by end of FY22," he added.

Mylan and Biocon Biologic's insulin glargine has received regulatory approval in more than 45 countries and is the third product approved by FDA through the Mylan-Biocon Biologics collaboration.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)